Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Sidell, Douglas R. , Balakrishnan, Karthik , Best, Simon R. , Zur, Karen B. , Buckingham, Julia C., Alarcón, Alessandro de , Baroody, Fuad M. , Bock, Jonathan M. , Boss, Emily F. , Bower, Charles M. , Clarke, Jeffrey , Clarke, Kevin D., Cocciaglia, Alejandro , Cotton, Robin T., Cuestas, Giselle , Davis, Kara L. , Defagó, Victor, Dikkers, Frederik G. , Dossans, Ines, Guerra, Walter Florez , Fox, Elizabeth , Friedman, Aaron D. , Grant, Nazaneen N. , Hogikyan, Norman D. , Johnson, Kaalan , Johnson, Liane B. , Johnson, Romaine F. , Kelly, Peggy, Klein, Adam M. , Lawlor, Claire M. , Levy, Alejandro G., Licameli, Greg R. , Long, Steve, Manrique, Dayse , McMurray, J. Scott , Meister, Kara D. , Messner, Anna H. , Möhr, Michael , Mortelliti, Anthony J., Novakovic, Daniel , Ongkasuwan, Julina , Piersiala, Krzysztof , Prager, Jeremy D. , Pransky, Seth M. , Raynor, Tiffany , Rodríguez, Hugo, Rodríguez, Verónica P., Scatolini, María Laura , Scheffler, Patrick , Smith, David F. , Smith, Lee P., Smith, Marshall E. , Smith, Richard J. , Sorom, Abraham, Steinberg, Amalia, Stith, John A., Thompson, Dana M. , Thompson, Jerome W. , Varela, Patricio, White, David R. , Wineland, Andre , Yang, Christina J. , Zdanski, Carlton J. , Derkay, Craig S. , Zur, Karen , de Alarcón, Alessandro , Campisi, Paolo , Friedman, Aaron D , Hamdi, Osama , Johnson, Romaine F , Leboulanger, Nicolas , Meister, Kara D , Novakovic, Daniel , Ongkasuwan, Julian , Prager, Jeremy D , Rinkel, Rico N P M , Smith, David F , Wineland, Andre M , Sidell, Douglas R , Davis, Kara L , Balakrishnan, Karthik , Buckingham, Julia, Chen, Sharon , Hamdi, Osama A. , Leboulanger, Nicolas , Lam, Derek J. , Long, Steve, Lott, David G. , Mudd, Pamela A. , Peer, Shazia , Preciado, Diego A. , Russell, John

Mayo Clinic

The Laryngoscope | January 8, 2021 | Volume: 131 | Issue: 6 | Pages: No page available

10.1002/lary.29343 | PMID 33405268 Get It

Objectives/HypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.Study DesignDelphi method‐based survey series.MethodsA multidisciplinary, multi‐institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work‐up.ResultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).ConclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best‐practice applications of systemic bevacizumab for patients with early‐onset or less‐severe disease phenotypes.Level of Evidence5 Laryngoscope, 131:E1941–E1949, 2021
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia
Ding, Husheng, McGehee, Cordelia D. , Kohorst, Mira A. , Koh, Brian D. , Venkatachalam, Annapoorna , Meng, X. Wei, Schneider, Paula A., Flatten, Karen S., Peterson, Kevin L. , Lee, Sun Hee , Patnaik, Mrinal M. , Webster, Jonathan , Karp, Judith E. , Pratz, Keith W. , Karnitz, Larry M., Vincelette, Nicole D. , Correia, Cristina , Webster, Jonathan A , Smith, B Douglas , Karp, Judith E , Kaufmann, Scott H , Correia, Cristina , Ghiaur, Gabriel , Smith, B. Douglas , Li, Hu , Kaufmann, Scott H. , Lee, Sun-Hee

Mayo Clinic

Cancer Research | January 7, 2021 | Volume: 81 | Issue: 10 | Pages: 2666-2678

10.1158/0008-5472.can-20-1504 | PMID 33414171 Get It

Abstract Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the same cytotoxic mechanism. Here we observed that CHK1 inhibition induces apoptosis in a subset of acute leukemia cell lines in vitro, including TP53-null acute myeloid leukemia (AML) and BCR/ABL–positive acute lymphoid leukemia (ALL), and inhibits leukemic colony formation in clinical AML samples ex vivo. In further studies, downregulation or inhibition of CHK1 triggered signaling in sensitive human acute leukemia cell lines that involved CDK2 activation followed by AP1-dependent TNF transactivation, TNFα production, and engagement of a TNFR1- and BID-dependent apoptotic pathway. AML lines that were intrinsically resistant to CHK1 inhibition exhibited high CHK1 expression and were sensitized by CHK1 downregulation. Signaling through this same CDK2–AP1–TNF cytotoxic pathway was also initiated by ATR or WEE1 inhibitors in vitro and during CHK1 inhibitor treatment of AML xenografts in vivo. Collectively, these observations not only identify new contributors to the antileukemic cell action of CHK1, ATR, and WEE1 inhibitors, but also delineate a previously undescribed pathway leading from aberrant CDK2 activation to death ligand–induced killing that can potentially be exploited for acute leukemia treatment. Significance: This study demonstrates that replication checkpoint inhibitors can kill AML cells through a pathway involving AP1-mediated TNF gene activation and subsequent TP53-independent, TNFα-induced apoptosis, which can potentially be exploited clinically.
Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents
Miller, Matthew A. , Molina, Kyle C. , Gutman, Jonathan A. , Scherger, Sias , Lum, Jessica , Mossad, Sherif B. , Burgess, Mary Jo , Chuang, Sally T, Jacobs, Samantha E, Melendez, Dante P. , Shah, Dimpy P. , Zimmer, Andrea , Syed, Sadia, Walker, Randall C., Poeschla, Eric M. , Abidi, Maheen Z. , Abidi, Maheen Z , Abidi, Maheen Z , Burgess, Mary, Cheng, Matthew Pellan , Jacobs, Samantha E, Sohail, M. Rizwan , Syed, Sadia

Mayo Clinic

Open Forum Infectious Diseases | December 30, 2020 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaa646 | PMID 33575424 Get It

Abstract Background The survival benefit of combination antifungal therapy for invasive mucormycosis (IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT) is not well defined. Methods This multicenter, retrospective study included HM and HCT recipients with proven or probable IM between January 1, 2007 and December 31, 2017 from 10 transplant centers across North America. Results Sixty-four patients with proven (n = 47) or probable (n = 17) IM defined by 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) consensus definitions were included. Thirty-nine (61%) were HCT recipients (95% allogeneic). Sites of infection included rhino-orbital-cerebral (33), pulmonary (30%), disseminated (19%), gastrointestinal (3%), and cutaneous (3%). Surgical debridement was performed in 66%. Initial antifungal treatment consisted of the following: lipid formulation of amphotericin B (AmB) alone (44%), AmB + posaconazole (25%), AmB + echinocandin (13%), AmB + isavuconazole (8%), posaconazole alone (5%), and isavuconazole alone (3%). All-cause mortality at 30 days and 1 year were 38% and 66%, respectively. Initial treatment with AmB plus posaconazole or isavuconazole (n = 28) was associated with a trend toward lower treatment failure compared with AmB (n = 21) (42% vs 64%, P = .136). Conclusions Long-term survival with IM among HM and HCT populations remains poor. However, initial use of AmB + azole in conjunction with surgery may result in less treatment failure. More evidence from prospective controlled studies is needed to confirm this observation.
A 29-Year-Old with Chronic Abdominal Pain; Beyond Helicobacter pylori
Chesdachai, Supavit , Helou, Emelie F. , Siechen, Kathleen D, Chesdachai, Supavit , Siechen, Kathleen D., Alpern, Jonathan D.

Mayo Clinic

Clinical Infectious Diseases | December 29, 2020 | Volume: 73 | Issue: 2 | Pages: 341-343

10.1093/cid/ciaa1920 | PMID 34265853 Get It

“July Effect” Revisited: July Surgeries at Residency Training Programs are Associated with Equivalent Long-term Clinical Outcomes Following Lumbar Spondylolisthesis Surgery
Chan, Andrew K. , Patel, Arati , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Shaffrey, Christopher I. , Potts, Eric A. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S. , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Choy, Winward , Haid, Regis W., Mummaneni, Praveen V. , Alvi, Mohammed A, Alvi, Mohammed Ali , Guan, Jian

Mayo Clinic

Spine | December 29, 2020 | Volume: 46 | Issue: 12 | Pages: 836-843

10.1097/brs.0000000000003903 | PMID 33394990 Get It

Study Design. Retrospective analysis of a prospective registry. Objective. We utilized the Quality Outcomes Database (QOD) registry to investigate the “July Effect” at QOD spondylolisthesis module sites with residency trainees. Summary of Background Data. There is a paucity of investigation on the long-term outcomes following surgeries involving new trainees utilizing high-quality, prospectively collected data. Methods. This was an analysis of 608 patients who underwent single-segment surgery for grade 1 degenerative lumbar spondylolisthesis at 12 high-enrolling sites. Surgeries were classified as occurring in July or not in July (non-July). Outcomes collected included estimated blood loss, length of stay, operative time, discharge disposition, complications, reoperation and readmission rates, and patient-reported outcomes (Oswestry Disability Index [ODI], Numeric Rating Scale [NRS] Back Pain, NRS Leg Pain, EuroQol-5D [EQ-5D] and the North American Spine Society [NASS] Satisfaction Questionnaire). Propensity score-matched analyses were utilized to compare postoperative outcomes and complication rates between the July and non-July groups. Results. Three hundred seventy-one surgeries occurred at centers with a residency training program with 21 (5.7%) taking place in July. In propensity score-matched analyses, July surgeries were associated with longer operative times ( average treatment effect = 22.4 minutes longer, 95% confidence interval 0.9–449.0, P = 0.041). Otherwise, July surgeries were not associated with significantly different outcomes for the remaining perioperative parameters (estimated blood loss, length of stay, discharge disposition, postoperative complications), overall reoperation rates, 3-month readmission rates, and 24-month ODI, NRS back pain, NRS leg pain, EQ-5D, and NASS satisfaction score (P > 0.05, all comparisons). Conclusion. Although July surgeries were associated with longer operative times, there were no associations with other clinical outcomes compared to non-July surgeries following lumbar spondylolisthesis surgery. These findings may be due to the increased attending supervision and intraoperative education during the beginning of the academic year. There is no evidence that the influx of new trainees in July significantly affects long-term patient-centered outcomes. Level of Evidence: 3
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Kaufman, Jonathan L. , Gasparetto, Cristina , Schjesvold, Fredrik , Moreau, Philippe , Dunbar, Fengjiao, Vishwamitra, Deeksha , Unger, Stefanie, Macartney, Tammy, Yu, Yao , Ross, Jeremy A. , Hong, Wan‐Jen , Maciag, Paulo , Pauff, James M., Kumar, Shaji , Schjesvold, Fredrik H , Moreau, Philippe , Kaufman, Jonathan L , Touzeau, Cyrille , Facon, Thierry T.F. , Boise, Lawrence , Jiang, Yanwen , Yang, Xiaoqing , Unger, Stefanie, Pesko, John Carl , Salem, Ahmed Hamed

Mayo Clinic

American Journal of Hematology | December 28, 2020 | Volume: 96 | Issue: 4 | Pages: 418-427

10.1002/ajh.26083 | PMID 33368455 Get It

AbstractVenetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combination in patients with t(11;14) positive relapsed/refractory (R/R) multiple myeloma (MM). This open‐label, multicenter study had two distinct phases (phase one [P1], phase two [P2]). Patients in both phases received VenDex (oral Ven 800 mg/day + oral Dex 40 mg [20 mg for patients ≥75 years] on days 1, 8, and 15, per 21–day cycle). The primary objective of the P1 VenDex cohort was to assess safety and pharmacokinetics. Phase two further evaluated efficacy with objective response rate (ORR) and very good partial response or better. Correlative studies explored baseline BCL2 (BCL‐2) and BCL2L1 (BCL‐XL) gene expression, cytogenetics, and recurrent somatic mutations in MM. Twenty and 31 patients in P1 and P2 with t(11;14) positive translocation received VenDex. P1/P2 patients had received a median of 3/5 lines of prior therapy, and 20%/87% were refractory to daratumumab. Predominant grade 3/4 hematological adverse events (AEs) with ≥10% occurrence included lymphopenia (20%/19%), neutropenia (15%/7%), thrombocytopenia (10%/10%), and anemia (5%/16%). At a median follow‐up of 12.3/9.2 months, ORR was 60%/48%. The duration of response estimate at 12 months was 50%/61%, and the median time to progression was 12.4/10.8 months. In biomarker evaluable patients, response to VenDex was independent of concurrent del(17p) or gain(1q) and mutations in key oncogenic signaling pathways, including MAPK and NF‐kB. VenDex demonstrated efficacy and manageable safety in heavily‐pre‐treated patients with t(11;14) R/R MM.
Although Surgical Techniques Differ, Similar Outcomes Can Be Obtained When Operating After Single Versus Multiple Anterior Shoulder Dislocations
Bernard, Christopher D. , Leland, Devin P. , Keyt, Lucas K. , LaPrade, Matthew D. , Krych, Aaron J. , Dahm, Diane L., Barlow, Jonathan D. , Krych, Aaron J , Camp, Christopher L.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | December 26, 2020 | Volume: 3 | Issue: 1 | Pages: No page available

10.1016/j.asmr.2020.09.006 | PMID 33615260 Get It

Purpose To compare the differences in preoperative pathology, surgical technique, and overall outcomes between patients treated surgically after a single anterior glenohumeral joint dislocation and those undergoing surgery after multiple dislocations. Methods An epidemiologic database was used to identify all patients younger than 40 years undergoing surgery for anterior shoulder instability between January 1, 1994, and July 31, 2016, in a defined geographic area. Patient medical records were reviewed to obtain demographic information, patient history, physical examination findings, imaging findings, clinical progression, surgical details, and outcomes. Comparative analysis was performed between patients who underwent surgery after a single dislocation and those who underwent surgery after multiple preoperative dislocations. Results The study population consisted of 187 patients who had a single anterior shoulder dislocation (n = 55) or multiple anterior shoulder dislocations (n = 132) prior to surgery. The mean follow‐up period was 103.3 months (range, 0.3‐328.4 months). Demographic characteristics were not significantly different between groups. Although the presence of Hill‐Sachs lesions on radiographs was more common in the multiple‐dislocation group (42.1%) than in the single‐dislocation group (18.8%, P = .005), there were no other significant differences in concomitant pathology between groups. Latarjet procedures were more commonly performed in the multiple‐dislocation group (12.5% vs 2.1% in the single‐dislocation group, P = .04). There were no other significant differences in surgical techniques and characteristics between groups. Rates of survival free from recurrent instability ( P = .790), revision surgery ( P = .726), and progression to symptomatic osteoarthritis ( P = .588) were not significantly different between groups. Conclusions Although patients with multiple dislocations prior to surgery were more likely to show radiographic evidence of Hill‐Sachs lesions and undergo the Latarjet procedure than those who received surgery after a single dislocation, no significant differences in outcomes with respect to recurrent instability, revision surgery, or progression to symptomatic osteoarthritis were found between these 2 groups at long‐term follow‐up. Level of Evidence Level III, retrospective comparative study.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Neelapu, Sattva S. , Adkins, Sherry , Ansell, Stephen M. , Cairo, Mitchell S. , Friedberg, Jonathan W. , Levy, Ronald , Porter, David L. , Bishop, Michael R. , Cairo, Mitchell , Brody, Joshua , Kline, Justin Paul , Besien, Koen van , Werner, Michael, Bishop, Michael Russell

Mayo Clinic

Journal for ImmunoTherapy of Cancer | December 24, 2020 | Volume: 8 | Issue: 2 | Pages: e001235

10.1136/jitc-2020-001235 | PMID 33361336 Get It

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy
Walker, Jamie M. , Richardson, Timothy E. , Iida, Megan A., Foong, Chan, Shang, Ping , Attems, Johannes , Ayalon, Gai , Beach, Thomas G. , Bigio, Eileen H. , Budson, Andrew E. , Cairns, Nigel J. , Corrada, María M. , Cortés, Etty , Flanagan, Margaret E. , Franklin, Erin , Gearing, Marla , Glass, Jonathan D. , Hansen, Lawrence A. , Haroutunian, Vahram , Kawas, Claudia H. , Keene, C. Dirk , Kofler, Julia , Kovács, Gábor G. , Lee, Edward B. , Lutz, Mirjam I. , Masliah, Eliezer , McKee, Ann C. , Mesulam, M.‐Marsel, Nelson, Peter T. , Perrin, Richard J. , Pham, Thao, Purohit, Dushyant P. , Sakai, Kenji , Sano, Mary , Stein, Thor D. , Teich, Andrew F. , Trojanowski, John Q. , Troncoso, Juan C. , Vonsattel, Jean-Paul G., Weıntraub, Sandra , Woltjer, Randall L. , Yamada, Masahito , Yu, Lei , Crary, John F. , Seshadri, Sudha , Murray, Melissa, Seshadri, Sudha , Kovacs, Gabor G , Murray, Melissa E , Teich, Andrew F , Lee, Edward B , Farrell, Kurt , Dickson, Dennis W. , Fischer, Peter A. , Hof, Patrick R. , Honig, Lawrence S. , Mao, Qinwen , McMillan, Corey T. , Murray, Melissa E. , Poon, Wayne W. , Rissman, Robert A. , Schneider, Julie A. , Wolk, David A. , White, Charles L. , Flanagan, Margaret E

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | December 23, 2020 | Volume: 80 | Issue: 2 | Pages: 102-111

10.1093/jnen/nlaa153 | PMID 33367843 Get It

Abstract Primary age-related tauopathy (PART) is a neurodegenerative entity defined as Alzheimer-type neurofibrillary degeneration primarily affecting the medial temporal lobe with minimal to absent amyloid-β (Aβ) plaque deposition. The extent to which PART can be differentiated pathoanatomically from Alzheimer disease (AD) is unclear. Here, we examined the regional distribution of tau pathology in a large cohort of postmortem brains (n = 914). We found an early vulnerability of the CA2 subregion of the hippocampus to neurofibrillary degeneration in PART, and semiquantitative assessment of neurofibrillary degeneration in CA2 was significantly greater than in CA1 in PART. In contrast, subjects harboring intermediate-to-high AD neuropathologic change (ADNC) displayed relative sparing of CA2 until later stages of their disease course. In addition, the CA2/CA1 ratio of neurofibrillary degeneration in PART was significantly higher than in subjects with intermediate-to-high ADNC burden. Furthermore, the distribution of tau pathology in PART diverges from the Braak NFT staging system and Braak stage does not correlate with cognitive function in PART as it does in individuals with intermediate-to-high ADNC. These findings highlight the need for a better understanding of the contribution of PART to cognitive impairment and how neurofibrillary degeneration interacts with Aβ pathology in AD and PART.
Author response: TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS
Cunningham, Kathleen M. , Maulding, Kirstin , Ruan, Kai , Grima, Jonathan C., Sung, Hyun , Zuo, Zhongyuan , Song, Helen, Gao, Junli , Dubey, Sandeep Kumar , Şentürk, Mümine , Rothstein, Jeffrey D. , Zhang, Ke , Bellen, Hugo J. , Lloyd, Thomas E

Mayo Clinic

No container title available | December 23, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.59419.sa2 Get It